86.51

0.96% -0.8867

Kymera Therapeutics Inc (KYMR)

Overview News Price History Option Chain Financials Discussions Forecast

Kymera Therapeutics Inc stock is traded at $86.51, with a volume of 209.26K. It is down -0.96% in the last 24 hours and up +23.78% over the past month. Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

Previous Close:

$87.40

Open:

$87.16

24h Volume:

209.26K

Relative Volume:

0.22

Market Cap:

$6.94B

Revenue:

$58.89M

Net Income/Loss:

$-240.88M

P/E Ratio:

-27.91

EPS:

-3.1

Net Cash Flow:

$-239.96M

1W Performance:

+5.13%

1M Performance:

+23.78%

6M Performance:

+96.29%

1Y Performance:

+135.16%

1-Day Range:

$85.69

$89.49

1-Week Range:

$80.36

$89.49

52-Week Range:

$19.45

$103.00

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name

Kymera Therapeutics Inc

Sector

Healthcare (1117)

Industry

Biotechnology (619)

Phone

857-285-5314

Address

500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN

Employee

225

Twitter

Next Earnings Date

2025-08-01

Latest SEC Filings

KYMR's Discussions on Twitter

Compare KYMR vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KYMR Kymera Therapeutics Inc	86.69	6.99B	58.89M	-240.88M	-239.96M	-3.10
VRTX Vertex Pharmaceuticals Inc	485.77	121.15B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	784.21	82.43B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	829.07	52.25B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	330.72	44.59B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	366.39	40.07B	4.98B	69.60M	525.67M	0.5198

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Overweight
Jan-06-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-03-25	Resumed	Guggenheim	Buy
Oct-24-25	Reiterated	B. Riley Securities	Buy
Oct-21-25	Initiated	Mizuho	Outperform
Sep-18-25	Reiterated	H.C. Wainwright	Buy
Sep-17-25	Initiated	Barclays	Overweight
Sep-16-25	Initiated	RBC Capital Mkts	Outperform
Jul-30-25	Resumed	B. Riley Securities	Buy
Jul-03-25	Resumed	Morgan Stanley	Overweight
Jun-03-25	Upgrade	B. Riley Securities	Neutral → Buy
Jun-03-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-02-25	Upgrade	BofA Securities	Neutral → Buy
May-20-25	Resumed	Stifel	Buy
Mar-13-25	Initiated	Citigroup	Buy
Dec-10-24	Initiated	BTIG Research	Buy
Dec-06-24	Initiated	BMO Capital Markets	Market Perform
Dec-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-18-24	Initiated	Stephens	Overweight
Sep-09-24	Resumed	Leerink Partners	Outperform
Aug-26-24	Upgrade	Wolfe Research	Peer Perform → Outperform
Apr-22-24	Initiated	Oppenheimer	Outperform
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Jan-04-24	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Dec-19-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-30-23	Initiated	Truist	Buy
May-05-23	Upgrade	Raymond James	Mkt Perform → Outperform
Dec-06-22	Downgrade	Credit Suisse	Outperform → Neutral
Nov-08-22	Initiated	Raymond James	Mkt Perform
Aug-15-22	Initiated	Jefferies	Buy
Aug-03-22	Initiated	Goldman	Buy
Jul-20-22	Initiated	SVB Leerink	Mkt Perform
Apr-28-22	Initiated	Credit Suisse	Outperform
Mar-10-22	Initiated	JP Morgan	Neutral
Feb-10-22	Initiated	Wells Fargo	Overweight
Sep-30-21	Initiated	B. Riley Securities	Neutral
Sep-30-21	Initiated	Stifel	Buy
Sep-10-21	Downgrade	BofA Securities	Buy → Neutral
May-21-21	Initiated	UBS	Buy
Apr-14-21	Initiated	Berenberg	Buy
Dec-04-20	Initiated	H.C. Wainwright	Buy
Sep-15-20	Initiated	BofA Securities	Neutral
Sep-15-20	Initiated	Cowen	Outperform
Sep-15-20	Initiated	Guggenheim	Buy
Sep-15-20	Initiated	Morgan Stanley	Equal-Weight

View All

Kymera Therapeutics Inc Stock (KYMR) Latest News

07:06 AM

Patient Square Capital LP Lowers Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat

07:06 AM

Feb 21, 2026

Buybacks Report: Can Kymera Therapeutics Inc outperform under higher oil pricesGlobal Markets & Technical Pattern Based Buy Signals - baoquankhu1.vn

Feb 21, 2026

Feb 20, 2026

Kymera Therapeutics: The More This Biotech Spends, The Higher Its Valuation Rises (KYMR) - Seeking Alpha

Feb 20, 2026

What makes Kymera Therapeutics Inc. stock attractive to growth fundsWeekly Investment Report & Momentum Based Trading Signals - mfd.ru

Feb 20, 2026

Feb 19, 2026

Is Kymera Therapeutics Inc. forming a bullish divergence2025 Risk Factors & Daily Market Momentum Tracking - mfd.ru

Feb 19, 2026

BofA Upgrades Kymera Therapeutics (KYMR) to Buy, Lifts PT to $51 - MSN

Feb 19, 2026

Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - The Manila Times

Feb 19, 2026

Kymera Therapeutics (KYMR) to Release Earnings on Thursday - Defense World

Feb 19, 2026

Feb 18, 2026

Kymera earnings up next as protein degrader rally faces catalyst test - Investing.com Nigeria

Feb 18, 2026

Feb 17, 2026

Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More - AOL.com

Feb 17, 2026